Diffusion-weighted MRI in Multicenter Trials of Breast Cancer: A Useful Measure of Tumor Response?

Affiliations

¹ From the MRI Unit, Cancer Research UK Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, England.

Editorial

Nandita M deSouza. Radiology. 2018 Dec.

. 2018 Dec;289(3):628-629.

doi: 10.1148/radiol.2018181717. Epub 2018 Sep 4.

¹ From the MRI Unit, Cancer Research UK Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, England.

No abstract available

Comment in

Diffusion-weighted MRI in Multicenter Trials of Breast Cancer.
Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. Partridge SC, et al. Radiology. 2019 May;291(2):546. doi: 10.1148/radiol.2019190446. Epub 2019 Apr 2. Radiology. 2019. PMID: 30938630 No abstract available.

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. Partridge SC, et al. Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4. Radiology. 2018. PMID: 30179110 Free PMC article. Clinical Trial.